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C0 of tacrolimus between the two genotype groups without 
AZ. However, in patients who were co-administered AZ, 
the C0 values of tacrolimus were higher in patients with 
the CYP3A5*3/*3 allele than with the CYP3A5*1 allele 
(P = 0.034), although daily doses of Tac-QD in patients 
with CYP3A5*3/*3 were significantly lower than those 
with the CYP3A5*1 allele (P = 0.041). The cumulative 
incidence of acute kidney injury was higher in patients with 
the CYP3A5*3/*3 than with the CYP3A5*1 allele when AZ 
was co-administered. The decrement for daily dosage of 
Tac-QD was significantly greater in patients expressing the 
CYP3A5*3/*3 than the CYP3A5*1 allele.
Conclusions CYP3A5 genotyping may be useful for safe 
and effective immunosuppressive therapy with Tac-QD in 
HSCT patients in whom the use of AZ is anticipated.
Keywords Once-daily tacrolimus formulation · 
CYP3A5 polymorphism · Azole antifungal agent · 
Pharmacokinetics · Hematopoietic stem cell transplantation
Introduction
Tacrolimus has been widely used to prevent graft rejection 
following solid organ transplantation and hematopoietic 
stem cell transplantation (HSCT). Tacrolimus plus metho-
trexate is regarded as one of the standard methods of graft-
versus-host disease (GVHD) prophylaxis after allogeneic 
HSCT. Given that tacrolimus has a narrow therapeutic win-
dow and that there are inter- and intra-individual variations 
in pharmacokinetics, blood concentrations of tacrolimus 
are usually monitored to maintain adequate exposure and to 
prevent drug-related toxicities [1].
Tacrolimus is given intravenously in the early phase 
after HSCT and then switched to oral administration. Oral 
Abstract 
Background Tacrolimus is metabolized by cytochrome 
P450 (CYP) 3A4 and 3A5. We investigated the influence 
of CYP3A5 polymorphism and concurrent use of azole 
antifungal agents (AZ) on the pharmacokinetics of a once-
daily modified-release tacrolimus formulation (Tac-QD) 
in patients after hematopoietic stem cell transplantation 
(HSCT).
Design and methods Twenty-four patients receiving allo-
geneic HSCT were enrolled. Genotyping for CYP3A5*3 
was done by a PCR-restriction fragment length polymor-
phism method. Trough blood concentrations (C0) of tac-
rolimus were measured by chemiluminescence magnetic 
microparticle immunoassay. Continuous infusion of tacroli-
mus was administered from the day before transplantation 
and was switched to Tac-QD after adequate oral intake.
Results Thirteen patients had a CYP3A5*3/*3 genotype, 
and 11 patients had a CYP3A5*1/*1 or *1/*3 genotype. No 
significant difference was observed in daily dosages and the 
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tacrolimus was first developed as a twice-daily (BID: bis in 
die) formulation (Tac-BID). Then, a once-daily modified-
release (QD: quaque die) formulation of tacrolimus (Tac-
QD) was developed to provide more convenient dosing and 
to improve patient adherence [2]. In solid organ transplan-
tation, initial clinical trials showed that the pharmacoki-
netic parameters of Tac-BID and Tac-QD were equivalent 
on a mg for mg basis, and Tac-QD was well tolerated with 
similar efficacy and safety profiles to Tac-BID [3–6]. How-
ever, studies of the pharmacokinetics of Tac-QD adminis-
tration in the HSCT setting are few in number compared 
with solid organ transplantation. Thus, the pharmacokinet-
ics of inter-individual variations of blood concentration of 
tacrolimus in transplant patients with Tac-QD after HSCT 
are yet to be determined.
Many clinical and genetic factors affect the pharmacoki-
netics of tacrolimus [7]. Cytochrome P450 (CYP) 3A4, 
CYP3A5 and ATP-binding cassette subfamily B mem-
ber 1 (ABCB1) reportedly contribute to inter-individual 
variability in the absorption, metabolism and tissue dis-
tribution of tacrolimus. Moreover, CYP3A5 may play a 
dominant role over that of CYP3A4 in the metabolism 
of tacrolimus in individuals who express the CYP3A5 
enzyme [8–12]. CYP3A5 is polymorphically expressed, 
and more than 10 single nucleotide polymorphisms (SNPs) 
have been identified [9]. The most important SNP related 
to functional variation is CYP3A5 6986A > G, in which 
the wild-type allele is CYP3A5*1 and the variant allele is 
CYP3A5*3 [13]. Homozygous carriers of the CYP3A5*3 
gene (CYP3A5*3/*3) should lack functional CYP3A5 pro-
tein [14–18]. There are racial differences in the frequencies 
of CYP3A5 polymorphisms [15, 19–21]. The frequencies 
of CYP3A5*3/*3 were reported to be 56.7–60.5 % in Japa-
nese, 86 % in Caucasians and 23 % in the African-Ameri-
can population. Although there are many genetic variants of 
CYP3A4 and ABCB1, the majority of studies have failed to 
find an association between the CYP3A4 or ABCB1 geno-
types and tacrolimus pharmacokinetics [9]. These studies 
have demonstrated that trough blood concentrations or area 
under the blood concentration–time curve (AUC) of tacroli-
mus was higher in patients with the CYP3A5*3/*3 geno-
type than those with the CYP3A5*1 allele, and the required 
daily dosage of tacrolimus was significantly reduced.
Our colleagues have previously reported the impact of 
CYP3A5 polymorphism on the pharmacokinetics of tacroli-
mus in kidney transplantation patients receiving Tac-QD 
administration [22–25]. However, the effect of the CYP3A5 
genotype on the pharmacokinetics of Tac-QD in HSCT 
patients has yet to be clarified [13]. Although azole antifun-
gal agents (AZ) are most often used for the prevention as 
well as the treatment of these infections in HSCT patients, 
these agents interfere with the metabolism and transport of 
tacrolimus [26]. In addition, the magnitude of drug inter-
actions between AZs and tacrolimus differs between AZs 
(itraconazole = voriconazole > fluconazole) [27, 28]. Here, 
we investigated the safety and efficacy of Tac-QD in HSCT 
patients. We focused on CYP3A5 polymorphism and the 
interaction of Tac-QD with AZ.
Methods
Recipients and protocols of transplantation
This study was conducted as a single-institution, prospec-
tive cohort study to evaluate the safety and efficacy of Tac-
QD in allogeneic HSCT patients. The eligibility criteria 
for the present study were as follows: (1) HSCT patients 
were given the same immunosuppressive regimens for the 
prophylaxis of GVHD; (2) age > 16 years; (3) no hyper-
sensitivity to tacrolimus (Prograf® or Graceptor®); (4) no 
liver dysfunction [aspartate aminotransferase (AST) or 
alanine aminotransferase (ALT) level < fivefold the upper 
normal range and total bilirubin level < 2.0 mg/dL]; (5) no 
renal dysfunction (serum creatinine level < 2.0 mg/dL or 
creatinine clearance > 30 mL/min); and (6) no consump-
tion of drugs or food affecting CYP3A and ABCB1 func-
tion. Twenty-four patients (17 males and 7 females) who 
underwent allogeneic HSCT at Akita University Hospital 
between April 2012 and October 2014 were enrolled in this 
study.
Prophylaxis regimens against GVHD included tacroli-
mus and methotrexate in the majority of patients, or vari-
ations including mycophenolate mofetil. Continuous infu-
sion of 0.03 mg/kg/day tacrolimus was administered from 
the day prior to stem cell infusion. Tacrolimus adminis-
tration was converted from intravenous administration 
to once-daily oral intake after adequate oral intake was 
observed. A quadruple dose of intravenous daily dose as an 
initial Tac-QD was administrated orally. The target whole 
blood concentrations of tacrolimus were 10–20 ng/mL 
with continuous infusion and 5–10 ng/mL after switching 
to oral administration. The whole blood concentrations of 
tacrolimus were measured by chemiluminescence magnetic 
microparticle immunoassay (CMIA).
Intravenous infusion of micafungin was given to prevent 
fungal infection during the neutropenic phase. Seven days 
after switching from tacrolimus continuous infusion to 
Tac-QD, antifungal agents were switched from intravenous 
micafungin to oral AZ.
This study was approved by the Ethics Committee of 
the Akita University School of Medicine, and each patient 
provided written informed consent in accordance with the 
Declaration of Helsinki.
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Genotyping
DNA was extracted from a peripheral blood sample using 
the QIAamp Blood kit (Qiagen, Hilden, Germany) and 
stored at −80 °C until analysis. The CYP3A5*3 allele 
was detected using a PCR-restriction fragment length 
polymorphism (RFLP) method [20]. The results obtained 
from PCR–RFLP analyses were confirmed using a fully 
automated SNP detection system (prototype i-density™; 
ARKRAY, Kyoto, Japan). The results of CYP3A5 geno-
typing were not used to adjust Tac-QD dosage or to score 
acute GVHD.
Blood concentration of tacrolimus
Whole blood samples were collected with EDTA just prior 
to the morning administration of Tac-QD 4–7 days after 
switching from continuous infusion to Tac-QD. Also, 
samples were collected 4–7 days after switching from 
intravenous micafungin to oral AZ. During both periods, 
whole blood tacrolimus concentrations were measured 
every day to confirm the stability of tacrolimus trough 
concentrations. Whole blood tacrolimus concentrations 
were determined using CMIA on the Architect-i1000® 
system (Abbott Laboratories, Abbott Park, IL) according 
to the manufacturer’s instructions. The Architect tacroli-
mus assay is a semiautomated, robust and highly sensitive 
immunoassay. It represents an alternative approach for lab-
oratories that are not equipped with an LC-MSMS, and it 
meets the 1 ng/mL LOQ recommendation of the European 
Consensus Conference on Tacrolimus Optimization [29]. 
LOQ values for CMIA are reported to be 0.5–0.8 ng/mL, 
and CMIA exhibits cross-reactivity of 94 % to the tacroli-
mus active metabolite, 31-O-demethyl tacrolimus (M-II) 
[29, 30]. The reliable range of determination of tacrolimus 
with the Architect-i1000® instrument is between 0.5 and 
30 ng/mL [31, 32].
Definition of acute kidney injury
Acute kidney injury (AKI) was defined according to 
CTCAE version 4.0: serum creatinine increased 0.3 mg/
dL or more, or more than 1.5 times from the baseline of 
serum creatinine. Baseline serum creatinine was the value 
obtained before the start of conditioning therapy.
Statistical analyses
The primary endpoint of this study was the analysis 
of the pharmacokinetic behavior of Tac-QD based on 
CYP3A5 polymorphisms. The secondary endpoints were 
the assessments of the development of acute GVHD and 
the transplantation-related mortality on day 100. The 
Kolmogorov–Smirnov test was used to assess distribu-
tion. The clinical characteristics of the HSCT patients, 
dose-adjusted blood concentrations and changes in these 
parameters were expressed as medians (quartiles 1–3). The 
Chi-square test was used to examine differences in cat-
egorical data, except when the expected number of cells 
was <5, in which case the Fisher’s exact test was used. 
The Mann–Whitney U test was used to determine the sig-
nificance of difference between continuous values between 
the groups. The Wilcoxon paired signed-rank test was used 
to determine the significance of differences in continuous 
values within each patient. A receiver operating charac-
teristic (ROC) curve was used to determine the best cutoff 
values for predictive factors that had a minimum distance 
from the upper left corner to a point on the ROC curve. The 
proportion of patients showing no clinical events was esti-
mated using the Kaplan–Meier method. The time to clinical 
events was compared between the groups using the strati-
fied log-rank test. A P value <0.05 was considered to be 
statistically significant. For post hoc power analysis, an 
effect size was calculated in comparison with clinical char-
acteristics between recipients with or without AKI after co-
administration of AZs. An effect size >0.5 was considered 
clinically meaningful. Statistical analyses were performed 
using SPSS version 20.0 software for Windows (SPSS IBM 
Japan, Tokyo, Japan). Power was calculated using G*Power 
version 3.1 software.
Results
CYP3A5 genetic polymorphism and outcome 
after HSCT
The characteristics of patients are given in Table 1. The 
CYP3A5 genotype frequency was in Hardy–Weinberg equi-
librium [19]. Eleven patients had either the CYP3A5*1/*1 
or *1/*3 genotype, and 13 patients had the CYP3A5*3/*3 
genotype. There was no significant difference in the ages, 
body weights, underlying diseases, pre-HSCT disease sta-
tus, graft sources, extents of HLA allele matching or con-
ditioning regimens between the two groups. Three patients 
could not switch to oral AZ due to severe infection. Flu-
conazole was used in 15 of 21 patients who were given oral 
AZ. Three patients received itraconazole, whereas another 
3 patients were treated with voriconazole.
There was no transplantation-related mortality on day 
100 in the present study cohort (Table 2). Two patients with 
relapse of the underlying disease and two patients with 
fungal infection were noted. There was a significant dif-
ference in the cumulative incidence of grade III–IV severe 
acute GVHD between the patients with the CYP3A5*1 
allele and the CYP3A5*3/*3 allele (36 vs. 0 %, P = 0.017). 
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The incidence of AKI was higher in the CYP3A5*3/*3 
group than in the *1 allele group (46 vs. 9 %, respectively, 
P = 0.046).
Pharmacokinetics of Tac‑QD during administration 
of oral AZ
Without co-administration of oral AZ, neither the tacroli-
mus C0 nor the median daily dose of tacrolimus differed 
between the CYP3A5*3/*3 and the CYP3A5*1 allele 
groups (3.5 vs. 3.3 mg/day, respectively, P = 0.965 or 7.9 
vs. 4.9 ng/mL, P = 0.053) (Fig. 1a). On the other hand, 
in the presence of AZ, tacrolimus C0 values were higher in 
patients with the CYP3A5*3/*3 than with the CYP3A5*1 
allele (10.1 vs. 7.4 ng/mL, respectively, P = 0.034) 
(Fig. 1b). The daily dose of tacrolimus was significantly 
lower in patients with the CYP3A5*3/*3 allele than with 
the *1 allele (2.0 vs. 4.0 mg/day, respectively, P = 0.041).
AKI occurred in the CYP3A5*3/*3 group 
after co‑administration of AZ
Seven patients developed AKI in the present study. In order 
to properly study the impact of Tac-QD and co-adminis-
tration of AZ, we excluded the three patients who did not 
receive AZ and the one patient who developed AKI prior 
to the administration of Tac-QD (Table 3). The median 
tacrolimus C0 with administration of AZ in patients with 
AKI was about twice that of patients without AKI (16.3 vs. 
8.6 ng/mL, P = 0.020, effect size = 0.517). Furthermore, 
only the patients with the CYP3A5*3/*3 developed AKI 
(6/6 vs. 6/14 patients, P = 0.024, effect size = 0.535). AKI 
occurred within 14 days of starting co-administration of AZ 
(Supplementary Fig. 1).
The tacrolimus C0 value was higher after co-adminis-
tration of AZ in most patients than without, and AKI was 
observed only after co-administration of AZ (Fig. 2). The 
area under the ROC for the tacrolimus C0 to develop AKI 
after co-administration of AZ was 0.833, which gave the 
best sensitivity (83.3 %) and specificity (85.7 %) at a tac-
rolimus C0 threshold of 10.1 ng/mL (data not shown).
Eighty percent of the CYP3A5*3/*3 group were required 
to reduce the daily dose of Tac-QD by 50 % or more within 
14 days of co-administration of AZ (Fig. 3). The reduction 
in the Tac-QD dosage in patients with the CYP3A5*3/*3 
was significantly faster than those with the CYP3A5*1 
allele (P = 0.020).
Discussion
This is the first study to assess the inter-individual vari-
ability of tacrolimus blood concentrations in allogeneic 
HSCT patients who were given Tac-QD. The results 
were clearly dependent upon the CYP3A5 polymorphism. 
There are three clinically important findings in the pre-
sent study. First, the CYP3A5 polymorphism had a great 
influence on the blood concentrations of tacrolimus, even 
when the once-daily modified-release formulation was 
used. Second, the blood concentrations of tacrolimus 
in patients with CYP3A5*3/*3 was elevated markedly 
after co-administration of AZ, even when the patients 
Table 1  Characteristics of HSCT recipients
AML acute myeloid leukemia, MDS myelodysplastic syndrome, ALL 
acute lymphoblastic leukemia, HSCT hematopoietic stem cell trans-
plantation, CR complete remission, BM bone marrow, PBSC periph-
eral blood stem cell, HLA human leukocyte antigen, GVHD graft-ver-
sus-host disease, MTX methotrexate, MMF mycophenolate mofetil, 
AZ azole antifungal agent
Characteristics CYP3A5 CYP3A5 P value
*1/*1 or *1/*3 *3/*3
Number of recipients 11 13
Male/female 8/3 9/4
Age [years, median (range)] 39 (21–63) 55 (36–65) 0.124
Body weight [kg, median 
(range)]
51 (49–66) 61 (49–69) 0.825
Diagnosis 0.622
 AML/MDS 8 11
 ALL 3 2
State before HSCT 0.265
 CR1 2 4
 CR2 or CR3 3 5
 Non-remission 6 4
Graft source 0.247
 BM from unrelated donors 10 8
 PBSC from sibling donors 0 2
 Umbilical cord blood 1 3
HLA allele matching 0.543
 5/8 1 2
 6/8 2 0
 7/8 2 7
 8/8 6 4
Conditioning 0.271
 Reduced intensity 3 7
 Myeloablative 8 6
GVHD prophylaxis 0.397
 MTX 11 11
 MMF 0 1
 MTX + MMF 0 1
In combination with AZ 0.855
 Fluconazole 7 8
 Itraconazole 1 2
 Voriconazole 1 2
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had been given fluconazole, which is recognized as hav-
ing the lowest CYP3A4 inhibitory activity among AZs. 
Finally, the CYP3A5*3/*3 group with AZ developed AKI 
when the blood concentrations of tacrolimus were over 
10.1 ng/mL.
Our colleagues previously reported that the CYP3A5 
polymorphism had no impact on the dose-adjusted AUC0–
24 of tacrolimus during continuous intravenous infusion 
in kidney transplantation patients. However, the bioavail-
ability of oral tacrolimus was higher for the CYP3A5*3/*3 
group than for the CYP3A5*1 allele group [33]. Also in the 
present study, we investigated the pharmacokinetics of tac-
rolimus when switching from intravenous infusion to oral 
administration and antifungal agents. AZ has a stronger 
inhibitory effect on CYP3A4 activity than on CYP3A5 in 
the small intestine [27, 28], and tacrolimus is metabolized 
by CYP3A4 in patients expressing CYP3A5*3/*3. As a 
result of CYP3A4 inhibition with AZ in the small intestine, 
we found that the C0 of tacrolimus was elevated markedly 
in CYP3A5*3/*3 patients after co-administration of AZ 
Table 2  Acute GVHD, TRM, relapse, fungal infection and AKI dur-
ing the first 100 days
GVHD graft-versus-host disease, TRM transplantation-related-mortal-
ity, AKI acute kidney injury
CYP3A5  
genotype






 Grade 0 5 8
 Grade 1 1 1
 Grade 2 1 4
 Grade 3 3 0
 Grade 4 1 0
Acute GVHD 0.017
 Grade 0–2 7 13
 Grade 3–4 4 0
TRM 0 0
Relapse 1 1 0.902
Fungal infection 1 1 0.902
AKI 1 6 0.046
Fig. 1  Comparison of doses (box and whiskers plots) and the tacroli-
mus trough levels (open circles) between the CYP3A5*1*1 + *1/*3 
group and the *3/*3 group. a Before co-administration of AZ and b 
after co-administration of AZ. Graphical analysis was performed 
using an SPSS box and whiskers plot. The box spans data between 
two quartiles (IQR), with the median represented as a bold horizontal 
line. The ends of the whiskers (vertical lines) represent the smallest 
and largest values that were not outliers. The gray circles represent 
the outlier of dose. AZ azole antifungal agent
116 Cancer Chemother Pharmacol (2016) 78:111–118
1 3
(Fig. 1). It has been reported that the blood concentration 
of tacrolimus was higher in patients with the CYP3A5*3/*3 
than those with the CYP3A5*1 allele in the absence of co-
administration of AZ in HSCT and kidney transplantation 
[17, 34]. We previously confirmed that the influence of 
CYP3A5 polymorphism on the tacrolimus dosage became 
evident 14 days after kidney transplantation [35]. Between 
the two genotypes, we did not observe a significant differ-
ence in the C0 value of tacrolimus or daily doses of Tac-QD 
before co-administration of oral AZ. However, it may be 
too short a time to observe differences in the blood con-
centration and doses of tacrolimus after switching to oral 
tacrolimus.
CYP3A5 is expressed in the liver and small intestine [8, 
36, 37], and it plays a key role in the small intestine [15]. 
The interaction between tacrolimus and AZ is depicted in 
Fig. 3. In patients with the CYP3A5*1 allele, tacrolimus 
can be metabolized by CYP3A5 in the intestinal epithe-
lium when oral AZ is given, resulting in inhibition of 
CYP3A4 activity. In contrast, the metabolism of tacroli-
mus in the CYP3A5*3/*3 group proceeds only through 
CYP3A4 in the presence of oral AZ. Since HSCT recipi-
ents are at high risk of developing invasive fungal infec-
tion [23], antifungal agents are commonly used therapeu-
tically and/or prophylactically. Many factors contribute to 
variability in the clinical significance of drug interactions 
between tacrolimus and AZ [27, 34, 38, 39]. Although 
the strong inhibition of CYP3A4 and P-glycoprotein by 
itraconazole is well known, many reports suggested that 
the influence of fluconazole on CYP3A4 may be less 
than other AZ agents [26–28]. In the present study, 15 
patients were given fluconazole and eight of them carried 
the CYP3A5*3/*3. Four patients who were given flucona-
zole in the CYP3A5*3/*3 group showed nephrotoxicity 
(Fig. 2). Kuypers et al. [40] reported similar results, in that 
the CYP3A5*3/*3 patients who were given fluconazole 
were more frequently exposed to supra-therapeutic tacroli-
mus C0. Our study suggests that co-administration of flu-
conazole with Tac-QD in the CYP3A5*3/*3 may cause not 
only elevation of tacrolimus blood concentrations but also 
kidney injury.
Tacrolimus has a narrow therapeutic window in HSCT, 
and Yano et al. [41] reported that the modification of Tac-
QD to maintain a whole tacrolimus C0 above 7.5 ng/mL 
may be as effective as Tac-BID, and no patient developed 
grade III–IV acute GVHD. On the other hand, we dem-
onstrated that nephrotoxicity of tacrolimus may increase 
when tacrolimus C0 was above 10.1 ng/mL (Fig. 2). By 
Table 3  Comparison of clinical characteristics between recipi-
ents with or without AKI after co-administration of azole antifungal 
agents
AKI acute kidney injury
With AKI Without AKI P value
Sex 0.613
 Male 4 10
 Female 2 4
CYP3A5 genotypes 0.024
 *1/*1 or *1/*3 0 8
 *3/*3 6 6
Age [years, median 
(range)]
60 (39–63) 53 (37–61) 0.353
Body weight [kg,  
median (range)]
55.1 (46.8–63.3) 61.5 (48.6–75.0) 0.097
In combination with 0.239
 Fluconazole 4 11
 Itraconazole 2 1
 Voriconazole 0 2
Dose of tacrolimus  
(mg/day)
2.0 (1.5–5.0) 3.5 (3.0–4.0) 0.659
Tacrolimus C0 (ng/mL) 16.3 (13.4–16.4) 8.6 (6.8–9.1) 0.020
Fig. 2  Comparisons of the tacrolimus trough levels according to the 
presence or absence of a co-administered AZ. Circles fluconazole; tri-
angles voriconazole; boxes itraconazole; closed figures patients with 
AKI. AZ azole antifungal agent, AKI acute kidney injury
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maintaining the tacrolimus C0 under 10 ng/mL, we may 
prevent nephrotoxicity in patients who are given Tac-QD 
with AZ. As Ram et al. reported [1], a higher mean blood 
concentration of tacrolimus during the second week follow-
ing HSCT was also correlated with protection against grade 
III–IV acute GVHD (Supplementary Fig. 2). The number 
of subjects was quite small, and we could not identify the 
clinical significance of the blood concentration of tacroli-
mus and CYP3A5 genotype. Studies consisting of a large 
number of subjects will be needed.
Unlike kidney transplantation, the administration of 
antifungal agents is usually required for allogeneic HSCT. 
CYP3A5 genotyping may be useful for determination of 
the appropriate dose of Tac-QD and the selection of AZ, 
in order to avoid AKI as well as severe acute GVHD. We 
need further prospective study to determine whether appro-
priate therapeutic drug monitoring based on stratified doses 
of tacrolimus in the setting of CYP3A5 polymorphism can 
prevent AKI.
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